GlobeNewsWire
27 Mar 2026, 11:00 UTC · 32w ago
Impact · against what's priced in
Autolus shows strong commercial momentum for AUCATZYL with a projected shift to positive gross margins and revenue guidance of $120M-$135M for 2026. Real-world safety data and a cash runway extending to Q4 2027 reduce immediate financial risk and support further market penetration.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish
Autolus expects to shift to a positive gross margin in 2026 due to improved manufacturing plant utilization and operational efficiencies.
More positive than 93% of claims this week
The company projects 2026 net product revenue for AUCATZYL to be between $120 million and $135 million.
So whatProvides a concrete baseline for valuation and commercial success of their primary product.
Continue reading
5 related stories
The company's shift to positive gross margin in 2026, combined with net product revenue guidance of $120 million to $135 million and a cash runway into Q4 2027, establishes a concrete path toward profitability.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 85% of claims this week
Current and projected cash reserves are expected to fund operations into Q4 2027.
So whatReduces immediate dilution risk and provides a clear runway for pipeline development and commercial scaling.
More positive than 76% of claims this week
Real-world data from the ROCCA consortium confirms high clinical activity for AUCATZYL with only 3% of patients experiencing high-grade ICANS.
More positive than 62% of claims this week
Autolus is executing pivotal studies in pediatric B-ALL (CATULUS) and severe lupus nephritis (LUMINA), with a Phase 1 study in progressive MS (BOBCAT).
More positive than 49% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
Strong first year of AUCATZYL launch, positive real-world data, and projected shift to positive gross margin in 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
30m ago
+2.3%
Price agrees with the score
$1.32 vs $1.29 close before publication (Mar 26) · not market-adjusted
AUTL chart →
